209 related articles for article (PubMed ID: 7150357)
1. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
Moore EC
Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
[TBL] [Abstract][Full Text] [Related]
2. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
3. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
Kensler TW; Jayaram HN; Cooney DA
Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
Kensler TW; Reck LJ; Cooney DA
Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876
[No Abstract] [Full Text] [Related]
5. Half of Saccharomyces cerevisiae carbamoyl phosphate synthetase produces and channels carbamoyl phosphate to the fused aspartate transcarbamoylase domain.
Serre V; Guy H; Penverne B; Lux M; Rotgeri A; Evans D; Hervé G
J Biol Chem; 1999 Aug; 274(34):23794-801. PubMed ID: 10446140
[TBL] [Abstract][Full Text] [Related]
6. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Monks A; Anderson LW; Strong J; Cysyk RL
J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
[TBL] [Abstract][Full Text] [Related]
7. Overproduction of the first three enzymes of pyrimidine nucleotide biosynthesis in Drosophila cells resistant to N-phosphonacetyl-L-aspartate.
Laval M; Azou Y; Giorgi D; Rosset R
Exp Cell Res; 1986 Apr; 163(2):381-95. PubMed ID: 2869965
[TBL] [Abstract][Full Text] [Related]
8. Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography.
Grem JL; Drake JC; Allegra CJ
Anticancer Drugs; 1993 Oct; 4(5):545-54. PubMed ID: 8292811
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
Friedman J; Moore EC; Hall SW; Loo TL
Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
[TBL] [Abstract][Full Text] [Related]
10. Properties of single-step mutants of Syrian hamster cell lines resistant to N-(phosphonacetyl)-L-aspartate.
Zieg J; Clayton CE; Ardeshir F; Giulotto E; Swyryd EA; Stark GR
Mol Cell Biol; 1983 Nov; 3(11):2089-98. PubMed ID: 6656764
[TBL] [Abstract][Full Text] [Related]
11. Pyrimidine biosynthesis in Plasmodium berghei.
Hill B; Kilsby J; McIntosh RT; Wrigglesworth R; Ginger CD
Int J Biochem; 1981; 13(3):303-10. PubMed ID: 6260538
[No Abstract] [Full Text] [Related]
12. In situ properties of Helicobacter pylori aspartate carbamoyltransferase.
Burns BP; Mendz GL; Hazell SL
Arch Biochem Biophys; 1997 Nov; 347(1):119-25. PubMed ID: 9344472
[TBL] [Abstract][Full Text] [Related]
13. MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification.
Chernova OB; Chernov MV; Ishizaka Y; Agarwal ML; Stark GR
Mol Cell Biol; 1998 Jan; 18(1):536-45. PubMed ID: 9418900
[TBL] [Abstract][Full Text] [Related]
14. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
15. Studies on channeling of carbamoyl-phosphate in the multienzyme complex that initiates pyrimidine biosynthesis in rat ascites hepatoma cells.
Otsuki T; Mori M; Tatibana M
J Biochem; 1982 Nov; 92(5):1431-7. PubMed ID: 6130083
[TBL] [Abstract][Full Text] [Related]
16. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
17. Induction of CAD gene amplification by restriction endonucleases in V79,B7 Chinese hamster cells.
Cavolina P; Agnese C; Maddalena A; Sciandrello G; Di Leonardo A
Mutat Res; 1989; 225(1-2):61-4. PubMed ID: 2563307
[TBL] [Abstract][Full Text] [Related]
18. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
Jacobsen LB; Putnam JE; Sawick DP; Cassady JM; Morré DJ
Life Sci; 1988; 42(8):913-8. PubMed ID: 3343891
[TBL] [Abstract][Full Text] [Related]
19. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
